Physician profile
Nancy E Binford
NPI 1508891169
$1,359.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $188 · 2021: $223 · 2022: $512 · 2023: $186 · 2024: $31.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $283.45 | 2019-2022 | |
| Exeltis, USA INC. | $255.71 | 2019-2023 | Slynd |
| Mayne Pharma Commercial LLC | $229.63 | 2022-2023 | |
| Abbvie INC. | $216.91 | 2019-2023 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $101.46 | 2021-2022 | |
| Scynexis, INC. | $58.91 | 2022 | |
| Astellas Pharma US INC | $44.06 | 2023 | Veozah, Myrbetriq |
| Allergan, INC. | $32.21 | 2019 | |
| Organon LLC | $31.96 | 2024 | |
| Lupin INC. | $31.73 | 2020 | |
| Avanos Medical | $20.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.09 | 2019 | |
| Duchesnay USA Incorporated | $16.38 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Binford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.